Ruxolitinib: An Oral Janus Kinase 1 and Janus Kinase 2 Inhibitor in the Management of Myelofibrosis

References

• . Vannucchi AM, Guglielmelli P, Tefferi A. Advances in understanding and management of myeloproliferative neoplasms. CA Cancer J Clin. 2009;59(3):171–191
   PubMed Web of Science ®Google Scholar
• . Vardiman JW, Thiele J, Arber DA, . The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood. 2009;114(5):937–951
   PubMed Web of Science ®Google Scholar
• . Quintás—Cardama A, Kantarjian H, Cortes J, Verstovsek S. Janus kinase inhibitors for the treatment of myeloproliferative neoplasias and beyond. Nat Rev Drug Disc. 2011;10(2):127–140
   PubMed Web of Science ®Google Scholar
• . Vianello F, Battisti A, Cella G, Marchetti M, Falanga A. Defining the thrombotic risk in patients with myeloproliferative neoplasms. Scientific World Journal. 2011;11:1131–1137
   Google Scholar
• . Cervantes F, Dupriez B, Pereira A, . New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment. Blood. 2009;113(13):2895–2901
   PubMed Web of Science ®Google Scholar
• . Vannucchi AM. Management of myelofibrosis. Hematology Am Soc Hematol Educ Program. 2011;2011:222–230
   PubMed Web of Science ®Google Scholar
• . Landolfi R, Di Gennaro L. Pathophysiology of thrombosis in myeloproliferative neoplasms. Haematologica. 2011;96(2):183–186
   PubMedGoogle Scholar
• . Barbui T, Barosi G, Birgegard G, . Philadelphia-negative classical myeloproliferative neoplasms: critical concepts and management recommendations from European LeukemiaNet. J Clin Oncol. 2011;29(6):761–770
   PubMed Web of Science ®Google Scholar
• . Kröger N, Holler E, Kobbe G, . Allogeneic stem cell transplantation after reduced-intensity conditioning in patients with myelofibrosis: a prospective, multicenter study of the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation. Blood. 2009;114(26):5264–5270
   PubMed Web of Science ®Google Scholar
• . Alchalby H, Yunus DRZabelina T, . Risk models predicting survival after reduced-intensity transplantation for myelofibrosis. Br J Haematol. 2012;157(1):75–85
   PubMed Web of Science ®Google Scholar
• . Kerbauy DM, Gooley TA, Sale GE, . Hematopoietic cell transplantation as curative therapy for idiopathic myelofibrosis, advanced polycythemia vera, and essential tlirombocythemia. Biol Blood Marrow Transplant. 2007;13(3):355–365
   PubMed Web of Science ®Google Scholar
• . JAKAFI [package insert]. Wilmington, DE: Incyte Corporation; 2011
   Google Scholar
• . Deisseroth A, Kaminskas E, Grillo J, . U.S. Food and Drug Administration approval: ruxolitinib for the treatment of patients with intermediate and high-risk myelofibrosis. Clin Cancer Res. 2012;18(12):3212–3217
   PubMed Web of Science ®Google Scholar
• . Michiels JJ, Berneman ZN, Schroyens W, Van Vliet HH. Pathophysiology and treatment of platelet-mediated microvascular disturbances, major thrombosis and bleeding complications in essential thrombo-cythaemia and polycythaemia vera. Platelets. 2004;15(2):67–84
   PubMed Web of Science ®Google Scholar
• . Shi JG, Chen X, McGee RF, . The pharmacokinetics, pharmacodynamics, and safety of orally dosed INCB018424 phosphate in healthy volunteers. J Clin Pharmacol. 2011;51(12):1644–1654
   PubMed Web of Science ®Google Scholar
• . Shilling AD, Nedza FM, Emm T, . Metabolism, excretion, and pharmacokinetics of [14C]INCB018424, a selective Janus tyrosine kinase 1/2 inhibitor, in humans. Drug Metab Dispos. 2010;38(11):2023–2031
   PubMed Web of Science ®Google Scholar
• . Verstovsek S, Kantarjian H, Mesa RA, . Safety and efficacy of INCB018424, a JAK1 and JAK2 inhibitor, in myelofibrosis. N Engl J Med. 2010;363(12):1117–1127
   PubMed Web of Science ®Google Scholar
• . Talpaz M, Hamburg SI, Jamieson K, . Preliminary safety and efficacy of ruxolitinib in patients (pts) with primary and secondary myelofibrosis (MF) with platelet counts (PC) of 50–100×109/L (ASCO Annual Meeting Proceedings). J Clin Oncol. 2012;30( suppl):6630
   Google Scholar
• . Verstovsek S, Mesa RA, Gotlib J, . A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis. N Engl J Med. 2012;366(9):799–807
   PubMed Web of Science ®Google Scholar
• . Harrison C, Kiladjian JJ, Al—Ali HK, . JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis. N Engl J Med. 2012;366(9):787–798
   PubMed Web of Science ®Google Scholar
• . Verstovsek S, Mesa RA, Gotlib J, . Consistent benefit of ruxolitinib over placebo in spleen volume reduction and symptom improvement across subgroups and overall survival advantage: results from COMFORT-I (ASH Annual Meeting Abstracts). Blood. 2011;118(21):278
   Web of Science ®Google Scholar
• . Harrison C, Kiladjian JJ, Gisslinger H, . Ruxolitinib provides reductions in splenomegaly across subgroups: an analysis of spleen response in the COMFORT-II study (ASH Annual Meeting Abstracts). Blood. 2011;118(21):279
   Web of Science ®Google Scholar
• . Mesa RA, Schwager S, Radia D, . The Myelofibrosis Symptom Assessment Form (MFSAF): an evidence-based brief inventory to measure quality of life and symptomatic response to treatment in myelofibrosis. Leuk Res. 2009;33(9):1199–1203
   PubMed Web of Science ®Google Scholar
• . Mesa R, Gotlib J, Gupta V, . Associations between improvements in myelofibrosis (MF) symptoms and quality of life measures with splenomegaly reduction in COMFORT-I: a randomized, double-blind, phase 3 trial of the JAK1 and JAK2 inhibitor ruxolitinib versus placebo in patients with MF (ASH Annual Meeting Abstracts). Blood. 2011;118(21):3842
   PubMedGoogle Scholar
• . Verstovsek S, Kantarjian HM, Estrov Z, . Long-term outcomes of 107 patients with myelofibrosis receiving JAK1/JAK2 inhibitor ruxolitinib: survival advantage in comparison to matched historical controls. Blood. 2012;120(6):1202–1209
   PubMed Web of Science ®Google Scholar
• . Tefferi A, Litzow MRPardanani A. Long-term outcome of treatment with ruxolitinib in myelofibrosis. N Engl J Med. 2011;365(15):1455–1457
   PubMed Web of Science ®Google Scholar
• . Verstovsek S, Mesa RA, Gotlib J, . Long-term outcome of ruxolitinib treatment in patients with myelofibrosis: durable reductions in spleen volume, improvements in quality of life, and overall survival advantage in COMFORT-I (ASH Annual Meeting Abstracts). Blood. 2012;120(21):800
   PubMedGoogle Scholar
• . Cervantes F, Kiladjian JJ, Niederwieser D, . Long-term safety, efficacy, and survival findings from Comfort-II, a phase 3 study comparing ruxolitinib with best available therapy (BAT) for the treatment of myelofibrosis (MF) (ASH Annual Meeting Abstracts). Blood. 2012;120(21):801
   Web of Science ®Google Scholar
• . Diamantidis MD. Ruxolitinib for myelofibrosis. N Engl J Med. 2012;366(21):2031
   PubMedGoogle Scholar
• . Tefferi A, Pardanani A. JAK inhibitors in myeloproliferative neoplasms: rationale, current data and perspective. Blood Rev. 2011;25(5):229–237
   PubMed Web of Science ®Google Scholar
• . Harrison C, Kiladjian JJ, Barosi G. Ruxolitinib for myelofibrosis. Author reply. N Engl J Med. 2012;366(21):2032–2035
   PubMedGoogle Scholar
• . www.ClinicalTrials.gov. Study to Determine the Safety and Efficacy of Ruxolitinib (INCB018424) in Patients With Polycythemia Vera or Essential Thrombocythemia. NCT00726232. Last updated October 22, 2012. Accessed October 25, 2012
   Google Scholar
• . Verstovsek S, Passamonti F, Rambaldi A, . Durable responses with the JAK1/JAK2 inhibitor, INCB018424, in patients with polycythemia vera (PV), essential thrombocythemia (ET) refractory or intolerant to hydroxyurea (HU) (ASH Annual Meeting Abstracts). Blood. 2010;116(21):313
   Web of Science ®Google Scholar
• . www.ClinicalTrials.gov. Study of Efficacy and Safety in Polycythemia Vera Subjects Who Are Resistant to or Intolerant of Hydroxyurea: JAK Inhibitor INC424 (INCB018424) Tablets Versus Best Available Care: (The RESPONSE Trial). NCT01243944. Last updated October 22, 2012. Accessed October 25, 2012
   Google Scholar
• . www.ClinicalTrials.gov. Switch Study From Hydroxyurea to Ruxolitinib for RELIEF of Polycythemia Vera Symptoms: The Relief Study. NCT01632904. Last updated January 9, 2013. Accessed January 11, 2013
   Google Scholar
• . www.ClinicalTrials.gov. Ruxolitinib (INCB018424) in Subjects With Primary Myelofibrosis, Post Essential Thrombocythemia-myelofibrosis and Post Polycythemia Vera-myelofibrosis. NCT01348490. Last updated October 16, 2012. Accessed October 25, 2012
   Google Scholar